Life Sciences
Huma is enabling biopharmaceutical and medical device companies to extract deeper insights into the use and performance of treatments in real world settings, through the collection and analysis of real world data.
The current situation
RWE is increasingly being used by biopharmaceutical and medical device companies to aid clinical trial design, regulatory approvals, surveillance, comparative effectiveness, and value in the real world.
Our offering
Huma's mobile platform technology supports the collection of patient-generated data as part of real world studies, such as registries and post-approval surveillance studies.
By partnering with leading RWE data generators, combining their real world data sources with digital patient-generated data, and through the application of AI technologies, we are enabling life sciences companies to extract data-driven insights from real world sources.
As part of these programs, Huma's portfolio of digital measures, biomarkers and technology for clinical trials are providing more objective, continuous insights into disease signs, symptoms, and patient behaviours and outcomes, for proactive, preventative health.
Our offering
Support physicians to make well-informed, data-driven improvements to the standard of care.
Improve insights into service provision and treatment patterns.
Improve the efficiency of care with improved decision making and care pathways.
Inform disease understanding and improve clinical trial designs.
Enable efficient expansion of drug labels into new indications.
Support post-marketing commitments to monitor drug safety.
Generate evidence of real world efficacy supporting the demonstration of value and pricing/reimbursement decisions with payers.
Enable more accurate assessments of clinical and economic advantages for a given therapy to support reimbursement.
Improve affordability of therapies and support movement to value-based pricing.
Increase patient access to therapies.
Ensure the right patients receive the right treatments.
Provide essential insights to verify the findings of randomised clinical trials (RCT).
Support expansion of drug labels into new indications.
Support post-marketing commitments to monitor the safety of marketed products.
Support physicians to make well-informed, data-driven improvements to the standard of care.
Improve insights into service provision and treatment patterns.
Improve the efficiency of care with improved decision making and care pathways.
Inform disease understanding and improve clinical trial designs.
Enable efficient expansion of drug labels into new indications.
Support post-marketing commitments to monitor drug safety.
Generate evidence of real world efficacy supporting the demonstration of value and pricing/reimbursement decisions with payers.
Enable more accurate assessments of clinical and economic advantages for a given therapy to support reimbursement.
Improve affordability of therapies and support movement to value-based pricing.
Increase patient access to therapies.
Ensure the right patients receive the right treatments.
Provide essential insights to verify the findings of randomised clinical trials (RCT).
Support expansion of drug labels into new indications.
Support post-marketing commitments to monitor the safety of marketed products.
Huma’s patient app accurately and securely captures high-frequency, real-life, patient-generated data from sensors, devices, eDiaries, ePROs, and ePerfOs.
Huma’s dashboard provides a continuous stream and early access to meaningful data.
Our platform is configurable from a diverse library of over 100 data capture modules to create tailored deployments for different therapeutic areas.
Why Huma?
Medical device grade platform built under a Quality Management System compliant with global security, privacy and regulatory requirements
Deployments with top 10 pharma companies, national governments, major healthcare providers and leading research institutions
Cloud agnostic platform that is ready to be deployed on any infrastructure and in any language
Our RWE platform and captured data can be efficiently transferred and integrated with other clinical data sources as well as other platforms (e.g. EDC in clinical trials or EMR in real world settings)
Our platform can be configured from a diverse library of 100+ data capture modules to create tailored deployments for different therapeutic areas
Medical device grade platform built under a Quality Management System compliant with global security, privacy and regulatory requirements.
Deployments with top 10 pharma companies, national governments, major healthcare providers and leading research institutions.
Cloud agnostic platform that is ready to be deployed on any infrastructure and in any language.
Our RWE platform and captured data can be efficiently transferred and integrated with other clinical data sources as well as other platforms (e.g. EDC in clinical trials or EMR in real world settings).
Our platform can be configured from a diverse library of 100+ data capture modules to create tailored deployments for different therapeutic areas.
Huma and Smith & Nephew partnered on a digital solution that remotely supports patients before and after knee/hip replacement surgery. The solution allows surgeons to assess pre-op readiness and collect valuable real-world data on patient outcomes, enabling S&N to have real-time visibility on the efficacy of their devices.
The dataset will form a central part of Smith & Nephew’s real-world evidence strategy, allowing an improved understanding of post-surgery outcomes.
